Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer

Martijn J.H.G. Simons, Valesca P. Retèl, Bram L.T. Ramaekers, Rogier Butter, Joanne M. Mankor, Marthe S. Paats, Joachim G.J.V. Aerts, Zakile A. Mfumbilwa, Paul Roepman, Veerle M.H. Coupé, Carin A. Uyl-de Groot, Wim H. van Harten, Manuela A. Joore^*

^*Corresponding author for this work

Health Technology & Services Research

Research output: Contribution to journal › Article › Academic › peer-review

19 Citations (Scopus)

145 Downloads (Pure)

1 results
- Title
- Start date(ascending)

Early cost-effectiveness model of whole genome sequencing as a molecular diagnostic test versus standard of care in locally advanced and metastatic (Stage IIIB,C/ IV) non-squamous non-small cell lung cancer
Simons, M. (Creator), Ramaekers, B. (Creator), Retèl, V. (Creator) & Joore, M. (Creator), Zenodo, 18 Aug 2021
DOI: 10.5281/zenodo.5112061, https://zenodo.org/record/5112062 and 2 more links, https://doi.org/10.5281/zenodo.5112062, https://zenodo.org/record/5112061 (show fewer)
Dataset